Jeil Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 1.69%

Jeil Pharmaceutical Co Ltd (271980) has an Asset Resilience Ratio of 1.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Jeil Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩8.87 Billion

≈ $6.01 Million USD Cash + Short-term Investments

Total Assets

₩526.12 Billion

≈ $356.54 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Jeil Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 271980 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Jeil Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Jeil Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩8.87 Billion	1.69%
Total Liquid Assets	₩8.87 Billion	1.69%

Asset Resilience Insights

Limited Liquidity: Jeil Pharmaceutical Co Ltd maintains only 1.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Jeil Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jeil Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Kamada TA:KMDA	Drug Manufacturers - Specialty & Generic	0.00%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Yipinhong Pharmaceutical Co Ltd Class A SHE:300723	Drug Manufacturers - Specialty & Generic	1.01%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%

Annual Asset Resilience Ratio for Jeil Pharmaceutical Co Ltd (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Jeil Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.95%	₩9.96 Billion ≈ $6.75 Million	₩510.57 Billion ≈ $346.01 Million	+1.19pp
2024-12-31	0.76%	₩3.98 Billion ≈ $2.70 Million	₩525.70 Billion ≈ $356.26 Million	+0.21pp
2023-12-31	0.55%	₩2.67 Billion ≈ $1.81 Million	₩487.33 Billion ≈ $330.25 Million	+0.52pp
2022-12-31	0.03%	₩142.46 Million ≈ $96.54K	₩456.89 Billion ≈ $309.63 Million	-0.45pp
2021-12-31	0.48%	₩2.04 Billion ≈ $1.38 Million	₩426.49 Billion ≈ $289.02 Million	-0.18pp
2020-12-31	0.66%	₩2.69 Billion ≈ $1.83 Million	₩409.66 Billion ≈ $277.62 Million	+0.66pp
2019-12-31	0.00%	₩4.76 Million ≈ $3.23K	₩401.59 Billion ≈ $272.15 Million	-0.09pp
2018-12-31	0.09%	₩350.00 Million ≈ $237.19K	₩402.90 Billion ≈ $273.04 Million	--

pp = percentage points

About Jeil Pharmaceutical Co Ltd

KO:271980 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$99.85 Million

₩147.34 Billion KRW

Market Cap Rank

#19295 Global

#951 in Korea

Share Price

₩10020.00

Change (1 day)

+0.10%

52-Week Range

₩9230.00 - ₩17390.00

All Time High

₩104611.38